BioNotebook: Astellas drops Aveo; Alexion, Prothelia collaborate; Akebia files, Audeo withdraws IPO
This article was originally published in Scrip
Executive Summary
Astellas, Aveo end tivozanib collaboration; Alexion gets option to buy Prothelia; and Audeo officially ends IPO effort, but Akebia seeks funds.